Cargando…
Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment
SIMPLE SUMMARY: The current clinical gold standard etoposide, doxorubicin, cisplatin, and mitotane (EDP-M) is not satisfying for the treatment of adrenocortical carcinoma (ACC). However, clinical translation of novel, preclinically promising therapies were unfortunately disappointing in recent years...
Autores principales: | Bothou, Christina, Sharma, Ashish, Oo, Adrian, Kim, Baek, Perge, Pal, Igaz, Peter, Ronchi, Cristina L., Shapiro, Igor, Hantel, Constanze |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391410/ https://www.ncbi.nlm.nih.gov/pubmed/34439352 http://dx.doi.org/10.3390/cancers13164200 |
Ejemplares similares
-
Non-Coding RNAs in Adrenocortical Cancer: From Pathogenesis to Diagnosis
por: Decmann, Abel, et al.
Publicado: (2020) -
A Comprehensive Investigation of Steroidogenic Signaling in Classical and New Experimental Cell Models of Adrenocortical Carcinoma
por: Sigala, Sandra, et al.
Publicado: (2022) -
Convergent allostery in ribonucleotide reductase
por: Thomas, William C., et al.
Publicado: (2019) -
The periodic table of ribonucleotide reductases
por: Ruskoski, Terry B., et al.
Publicado: (2021) -
New Insights in the Genetics and Genomics of Adrenocortical Tumors and Pheochromocytomas
por: Igaz, Peter
Publicado: (2022)